Our Company

Board of Directors

Mr. Mark Beaudet


Mark Beaudet is a co-founder of Paladin Labs Inc., a specialty pharmaceutical company focused on acquiring or in-licensing innovative pharmaceutical products, that was acquired by Endo International plc in 2014 for approximately $3.0 billion. Since Paladin’s founding in 1996, Mr. Beaudet served as a member of the board of directors and as the company’s Vice President of Sales and Marketing until 2011 when he became interim President and CEO. Following Endo’s acquisition of Paladin, Mr. Beaudet joined the Endo International plc. executive leadership team and continued to lead the Paladin team.
Mr. Beaudet is a member of the board of directors of the McGill University Health Center Foundation, Loyola High School and the Loyola High School Foundation.

Mr. Beaudet also serves on the board of Altus Formulation Inc., a privately held drug formulation and development company. He is a former member of the board and former Chair of the Regulatory Affairs Committee of Innovative Medicines Canada (formerly Rx&D – Canada’s Research Based Pharmaceutical Industry Association). In 2015 Mr. Beaudet was inducted into the Canadian Healthcare Marketing Hall of Fame.

Dr. Damon Smith

Founder and CEO

Damon Smith has over thirty years of international experience in the biopharmaceutical sector specializing in the transformation of early stage companies into market or exit ready organizations. During his career Damon has held leadership positions at Therapeutic Antibodies Inc.. Conjuchem Inc and Labopharm Inc. where he served as Senior Vice President R&D. During this period Dr. Smith participated in three successful IPO (raising over $400MM) numerous successful financings and the launch of 7 new products in multiple markets. In 2012 Dr. Smith founded Altus Formulation Inc where he has served as CEO for the past 8 years scaling the company and leading it to commercialization readiness via its international large pharma partners.

Along with Dr. Chamberland, Dr. Smith is a Founder of TALLC.

Dr. Guy Chamberland


Guy Chamberland, M.Sc., Ph.D., Master Herbalist, has served as Tetra Bio-Pharma’s Chief Executive Officer and Chief Scientific Officer since October 15, 2018. He held the positions of Interim Chief Executive Officer and Chief Scientific Officer respectively since April 2018 and June 2016. Dr. Chamberland’s extensive experience in both executive and scientific roles establish him as an expert in the biopharmaceutical space. Dr. Chamberland has more than two decades of experience in drug development for the North American pharmaceutical industry with specific expertise in regulatory affairs, and the development and management of clinical research protocols and clinical studies for botanical medicines. He was also a member of the investment committee of the venture capital fund, Fonds Bionvation, for 7 years.

Along with Dr. Smith and Dr. Kelly, Dr. Chamberland is a Founder of TALLC.

Mr. Sylvain Guenette
Mr. Guénette served as Vice-President, Finance from 2012 to end of 2019 for American Iron & Metal Company Inc., a metal recycling company operating internationally. Previously, Mr. Guénette was CFO at Labopharm Inc., a specialty pharmaceutical company with products commercialized internationally, listed on the TSX, and on NASDAQ where he worked from 2002 to 2012.. Prior to joining Labopharm, Mr. Guénette was Corporate Controller from 2001 to 2002 for Les Systèmes Proxima Ltée, a private software development company operating internationally and headquartered in Montreal. From 1994 to 2001, he held various finance or operations related positions within the Quebecor group. He also worked for Raymond Chabot Martin Paré from 1990 to 1994, as an external auditor.
Mr. Steeve Neron
Mr. Néron has more than three decades of experience in the pharmaceutical industry where challenging the reimbursement landscape factored prominently in his role, with demonstrated success in numerous therapeutic sectors including cardiology, rheumatology, endocrinology, women’s health, asthma/COPD, OTC and dermatology. Prior to joining Tetra Bio-Pharma he occupied a senior marketing position at Bausch Health Canada. Steeve has held various marketing, sales, finance, material management and business development positions and has worked to launch or rejuvenate numerous market-leading pharmaceutical brands including Aerius™ (antihistamine), Altace™ (hypertension), Ezetrol™ (cholesterol), Eliquis™ (anti-coagulant), Lodalis™ (cholesterol) and Contrave™ (Obesity).
Dr. Aurelia De Pauw
Aurelia holds a master’s degree and PhD in Science from the Gembloux Agro-Bio Tech, University of Liege and the University of Namur, Belgium. She followed this with a five-year post-doctoral position in the field of stem cell therapy. After establishing her career in basic sciences and regenerative therapy, she progressed from the laboratory bench to the bedside where she gained an even deeper appreciation of the impact of research on patients and caregivers. Aurelia has extensive experience in numerous therapeutic categories including oncology, drug abuse, endocrinology, dermatology and cardiology.

Management Team

Scientific Advisors


Phone: 514 883 3447

Email: info@tallcinc.com


TALLC issues new Corporate Presentation

Dr. Damon Smith at Biotech Show Case

TALLC at the Ophthalmology Innovation Summit

TALLC Corporation Announces Grant of New SmartCelle Patent for Enhanced Ocular Delivery of TA-A001

Tetra Bio-Pharma and Altus Formulation Form New Company “TALLC” to Exploit TA-A001

TALLC and IACTA to present at the H.C. Wainwright Bioconnect Conference: January 10-13, 2022

TALLC will present details of the SmartCelle insoluble drug delivery platform for ocular, parenteral and oral delivery and an update on t…https://lnkd.in/gAwAqwnQ

Load More...
TALLC Innovation in Vision

© TALLC Inc. 2020